Poltreg S.A. (WSE:PTG)

Poland flag Poland · Delayed Price · Currency is PLN
27.50
+1.10 (4.17%)
Feb 12, 2026, 5:00 PM CET
Market Cap128.24M -29.7%
Revenue (ttm)n/a -75.0%
Net Income-24.56M
EPS-5.27
Shares Out4.66M
PE Ration/a
Forward PE64.93
Dividendn/a
Ex-Dividend Daten/a
Volume4,908
Average Volume4,580
Open27.50
Previous Close26.40
Day's Range26.80 - 27.60
52-Week Range22.70 - 40.30
Beta0.74
RSI62.21
Earnings DateApr 16, 2026

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdańsk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 33
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.

Financial Statements